A newly developed PLD1 inhibitor ameliorates rheumatoid arthritis by regulating pathogenic T and B cells and inhibiting osteoclast differentiation

Immunol Lett. 2023 Nov:263:87-96. doi: 10.1016/j.imlet.2023.09.007. Epub 2023 Sep 16.

Abstract

Phospholipase D1 (PLD1), which catalyzes the hydrolysis of phosphatidylcholine to phosphatidic acid and choline, plays multiple roles in inflammation. We investigated the therapeutic effects of the newly developed PLD1 inhibitors A2998, A3000, and A3773 in vitro and in vivo rheumatoid arthritis (RA) model. A3373 reduced the levels of LPS-induced TNF-α, IL-6, and IgG in murine splenocytes in vitro. A3373 also decreased the levels of IFN-γ and IL-17 and the frequencies of Th1, Th17 cells and germinal-center B cells, in splenocytes in vitro. A3373 ameliorated the severity of collagen-induced arthritis (CIA) and suppressed infiltration of inflammatory cells into the joint tissues of mice with CIA compared with vehicle-treated mice. Moreover, A3373 prevented systemic bone demineralization in mice with CIA and suppressed osteoclast differentiation and the mRNA levels of osteoclastogenesis markers in vitro. These results suggest that A3373 has therapeutic potential for RA.

Keywords: Collagen-induced arthritis; Inflammatory cytokines; Osteoclastogenesis; Phospholipase D1; Rheumatoid arthritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arthritis, Experimental* / drug therapy
  • Arthritis, Experimental* / pathology
  • Arthritis, Rheumatoid* / drug therapy
  • Arthritis, Rheumatoid* / pathology
  • Cell Differentiation
  • Cytokines / genetics
  • Mice
  • Osteoclasts
  • Phospholipase D* / genetics
  • Phospholipase D* / pharmacology
  • Phospholipase D* / therapeutic use
  • Th17 Cells / pathology

Substances

  • phospholipase D1
  • Phospholipase D
  • Cytokines